2021 American Transplant Congress
Guiding Therapeutic Plasma Exchange for Amr Treatment in Lung Transplant Recipients Using Serial Dilution in Single Antigen Bead Assay
*Purpose: Development of donor‐specific antibodies (DSA) is associated with poor outcomes in lung transplantation. Patients who are presented with at least probable AMR require treatment;…2020 American Transplant Congress
Isolation of Preformed Antibodies from Whole Blood by Integrating Acoustics and Microfluidics in Sensitized Animal Model
*Purpose: Apheresis therapy refers to the separation, removal and/or exchange of unwanted blood components (red cells, white cells, platelets and/or plasma) by centrifugation and return…2020 American Transplant Congress
Navigating Through IgM Antibodies in Deceased Donor Kidney Transplants from A2/A2B Donors to B Recipients
University of Texas Medical Branch, Galveston, TX
*Purpose: Multiple studies have shown acceptable deceased donor transplant (DDT) outcomes from A2 and A2B donors into B recipients; however, concerns remain for acute rejection…2020 American Transplant Congress
Belatacept Removal by Plasmapheresis: Kinetics, Dose Adjustments and Clinical Recommendations
*Purpose: Belatacept (BELA), a protein immunosuppressant, has limited available pharmacokinetic (PK) data. Available PK data, limited to product development analyses, shows moderate intrapatient variability with…2020 American Transplant Congress
Posttransplant Prophylactic Therapy with IVIG/Plasmapheresis in Kidney Transplant Recipients with Preformed Donor-Specific Antibodies
Hospital Geral de Fortaleza, Fortaleza, Brazil
*Purpose: Patients with high levels of preformed donor-specific antibodies (DSA) are often not considered for kidney transplantation (KT), despite negative CDC-crossmatch, mainly in regions where…2020 American Transplant Congress
Effect of Therapeutic Plasma Exchange on Glomerular Filtration Rate in Patients with Acute Humoral Rejection
Nephrology and Transplant Division, CMN 20 de Noviembre, Ciudad de Mexico, Mexico
*Purpose: AMR is the main risk factor for graft loss, especially after the first post transplant year. Up to 80% of patients achieve response with…2020 American Transplant Congress
Efficacy and Safety of Pre-Emptive Plasma Exchange and Rituximab in Prevention of Recurrent Focal Segmental Glomerulosclerosis after Kidney Transplantation in High-Risk Patients
Imperial College Kidney and Transplant Center, Hammersmith Hospital, London, United Kingdom
*Purpose: Focal segmental glomerulosclerosis (FSGS) is considered the leading cause of nephrotic syndrome in the adult population. Following kidney transplantation (KT), the recurrence rate of…2020 American Transplant Congress
Outcomes of a Pre-Transplant Desensitization Protocol with Carfilzomib, Plasmapheresis, and IVIG for Broadly Sensitized Lung Transplant Candidates: A Case Series
*Purpose: The presence of anti-human leukocyte antigen (HLA) antibodies in lung transplant candidates leads to increased wait list times and antibody-mediated rejection (AMR) post-transplant. We…2020 American Transplant Congress
Impact of Rituximab and Apheresis Techniques in Acute Rejection Rates in ABO Incompatible Living Donor Kidney Transplant
*Purpose: ABO incompatibility (ABOi) is a widespread option of living kidney donor transplantation (LKDT). However, controversies in rejection, and death-censored graft survival rates are published,…2020 American Transplant Congress
Non-HLA Antibodies in Severe Post-Operative Thrombotic Microangiopathy among Kidney Transplant Recipients
University of North Carolina Hospitals, Chapel Hill, NC
*Purpose: From August 2018 until July 2019, an alarming 6% of kidney transplant recipients at this transplant center had biopsy-proven thrombotic microangiopathy (TMA) within 1…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »